BTIG upgraded Mersana Therapeutics to Buy from Neutral with a $6 price target. The firm believes upcoming catalysts this year could significantly de-risk the Dolasynthen platform and the lead ADC, XMT-1660, designed using the Dolasynthen technology, the analyst tells investors. The first readout expected at the ESGO meeting being held March 7-10 will provide data from the Uplift trial for UpRi and data from the Phase 1 trial for XMT-1592 is due on March 8, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRSN:
- Mersana Therapeutics Shares Corporate Presentation Update
- Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
- Mersana Therapeutics to Present at Upcoming Investor Conferences
- Mersana Therapeutics (MRSN) Q4 Earnings Cheat Sheet
- Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
